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There is a well known association between end stage renal disease and the development
of kidney cancer in the native kidney of patients requiring renal replacement therapy.There
is now emerging evidence that lesser degrees of renal insufﬁciency (chronic kidney dis-
ease, CKD) are also associated with an increased likelihood of cancer in general and kidney
cancer in particular. Nephropathological changes are commonly observed in the non-tumor
bearing portions of kidney resected at the time of partial and radical nephrectomy (RN). In
addition, patients with renal cancer are more likely to have CKD at the time of diagnosis
and treatment than the general population. The exact mechanism by which renal insufﬁ-
ciency transforms normal kidney cells into tumor cells is not known. Possible mechanisms
includeuremicimmuneinhibitionorincreasedexposuretocirculatingtoxinsnotadequately
cleared by the kidneys. Surgeons managing kidney tumors must have an increased aware-
ness of their patient’s renal functional status as they plan their resection. Kidney sparing
approaches, including partial nephrectomy (PN) or active surveillance in older and morbidly
ill patients, can prevent CKD or delay the further decline in renal function which is well
documented with RN. Despite emerging evidence that PN provides equivalent local tumor
control to RN while at the same time preventing CKD, this operation remains under utilized
in the United States and abroad. Increased awareness of the bi directional relationship
between kidney function and kidney cancer is essential in the contemporary management
of kidney cancer.
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INTRODUCTION
It is well known that end stage renal disease (ESRD) patients
requiring renal replacement therapy either by dialysis or trans-
plantation are at increased risk for developing cancer and at four
to ﬁvefold increased risk of developing renal cancer in their native
kidneys (Birkelan et al., 2000; Buell et al., 2005; Mandayam and
Shahinian,2008).MortalityrelatedtoESRDrelatedkidneycancer
depends upon the variable metastatic potentials of the tumor and
competing threats posed by complex cardiovascular and medical
diseaseswhichresultfromorcauseofthekidneydisease.Emerging
evidence now exists which also associates chronic kidney disease
(CKD) with a greater risk of cancer and kidney cancer in particu-
lar.Diffusenephropathologicalchangesarecommonlyobservedin
the non-neoplastic kidney at the time of nephrectomy for cancer.
These histopathological ﬁndings correlate with a greater baseline
risk of CKD in the kidney patient than the population at large.
It is not currently known whether the underlying damage to the
kidney is a carcinogenic event in and of itself or whether renal
dysfunction allows for carcinogenic toxins or immune inhibition
that then transforms normal kidney cells into cancer cells.
For surgeons planning operations on patients with renal
tumors, oncological goals of providing local tumor control by
radical or partial nephrectomy (PN) must now be tempered by
an understanding of the baseline renal functional health of the
patient and the potential impact of operation on overall renal
function. There is now abundant clinical evidence which suggests
radicalnephrectomy(RN)forsmallrenalmassesisovertreatment
fromanoncologicalperspectiveandcausesorworsenspre-existing
CKD. Knowledge of this bi directional relationship between kid-
ney function and kidney cancer is an essential component in the
management of kidney tumor patients.
THE PROBLEM OF KIDNEY CANCER
An estimated 60,920 new cases and 13,120 deaths from kidney
cancer occurred in the United States in 2011. Kidney cancer is
increasing at a rate of approximately 3% per year. Compared with
1971, this represents a ﬁvefold increase in incidence and twofold
increaseinmortality.Associatedriskfactorsincludehypertension,
smoking, obesity, and diabetes. Epidemiologic evidence suggests
an increase in all stages of renal cancer including the advanced
and metastatic cases (McLaughlin and Lipworth,2000; Ljungberg
et al., 2011). Approximately 30–40% of renal tumor patients will
either present with or later develop metastatic disease. The wide-
spread use of the modern abdominal imaging techniques (CT,
MRI, and ultrasound) over the last 20years, usually ordered to
evaluate non-speciﬁc abdominal and musculoskeletal complaints
or during unrelated cancer care, has changed the proﬁle of the
typicalrenaltumorpatientfromonewithamassive,symptomatic
tumor at presentation to one with a small, asymptomatic, renal
mass (<4cm) incidentally discovered in 70% of the cases (Russo,
www.frontiersin.org April 2012 | Volume 2 | Article 28 | 1Russo Renal insufﬁciency and cancer
2000).Overthelastfourdecades,evidencefromtheSEERdatabase
suggestsanincreaseintheincidenceof kidneycancerinblacks,an
American population less likely to have access to incidental tumor
detection and exposed to lesser rates of nephrectomy but more
likely to have unrecognized and untreated hypertension,diabetes,
and CKD. Despite this, mortality rates in blacks are equivalent to
whites raising the possibility that kidney cancer is less aggressive
in black patients (Lipworth et al., 2011).
Despitethissizeandstagemigration,kidneycancerspeciﬁcsur-
vival rates have not signiﬁcantly improved over the last 15years.
This disconnect suggests that aggressive treatment of smaller
tumors is not sufﬁcient to offset more virulent disease seen in
all stages in general or advanced stages in particular (Russo et al.,
2008). A survival rate of 90% or greater, depending on the tumor
histology, is expected for small tumors whether PN or RN is per-
formed (Kattan et al., 2001; Russo, 2010). We now understand
that renal cortical tumors are members of a complex family with
unique histopathology, cytogenetics, familial and hereditary syn-
dromes, and variable metastatic potentials. Approximately 20%
of patients with surgically resected renal masses will be a benign
lesion(i.e.,angiomyolipoma,oncocytoma,metanephricadenoma,
or hemorrhagic cyst), 25% will be an indolent tumor (papillary,
chromophobe carcinoma) with limited metastatic potential, and
54%willbethemorepotentiallymalignantconventionalclear-cell
carcinoma that accounts for 90% of the metastatic renal tumors
(Teloken et al., 2009;Algaba et al.,2011).
END STAGE RENAL DISEASE: ASSOCIATION WITH CANCER
AND KIDNEY CANCER
A deﬁnite association between malignancy and ESRD has been
reported (Matas et al., 1975; Cengiz, 2002). Stewart evaluated
28,855 patients who required renal replacement therapy and
reported a fourfold increased incidence of cancer. Immune deﬁ-
ciency related cancers were increased from 1.5-fold while on
dialysis to ﬁvefold after transplantation and the initiation of anti-
rejection medication. The authors speculated that this increase
after transplantation could be virally mediated (Stewart et al.,
2009). Liang matched 21,817 ESRD patients in Taiwan to patients
from the general population without ESRD and found the risk of
developing cancer was 64% higher in the ESRD patients (Liang
et al., 2011). Lee evaluated 4582 patients with ESRD and found
106 patients that developed cancer. The most common cancers
werefromtheGItract(51%),urinarytract(20%),andlung(8%).
Inthissubgroupof patients,69%of themortalitywasduetocan-
cer (Lee et al., 2009). Mosconi et al. (2011) evaluated 1184 Italian
patients with ESRD on a kidney transplant waiting list and found
cancers in 2.2% of patients, most of which were non-metastatic
with the most common arising from kidney and thyroid.
It has also been reported that ESRD patients have a higher
prevalence of renal cell carcinoma than the general populations
(IshikawaandKovacs,1993)anddistinctclinicalandpathological
features can be identiﬁed in ESRD patients. Neuzillet compared
the pathological features of 303 renal cancer patients with ESRD
to 947 sporadic renal cancer patients and found that the mean
age at diagnosis was younger (55 v 62), the mean tumor size was
smaller (3.7 vs. 7.3cm), more were asymptomatic (87 vs. 44%),
less were high stage (10 vs. 42%), less had nodal metastasis (3 vs.
12%) and less had distant metastasis (2 vs. 15%). After a median
followupof33months,13ESRD(4.3%)patientshaddiedofrenal
cancer vs. 261 (27.6%) from the sporadic tumor population. The
authorsconcludedthatRCCarisinginthenativekidneysof ESRD
patientsmayhaveamoreindolentnaturalhistory(Neuzillettetal.,
2011).Horadescribedpathologicalcharacteristicsofrenalcortical
tumorsin13ESRDpatients,whichincluded6bilateralprocedures,
for a total of 19 kidney specimens. In 13 kidneys the tumors were
multiple and in 6 solitary. Papillary and clear-cell tumors alone or
in combination were reported (Hora et al., 2008). Hajj reported
89 nephrectomies (including 10 bilateral) resected in 79 patients
withautosomaldominantpolycysticdisease(ADPKD),50of who
hadESRD.In11of the89kidneysresected,renalcancerwasfound
including1bilateraland3multifocaltumor.Of these,58.3%were
clear cell and 41.7% tubulopapillary carcinomas. The authors cal-
culated that the prevalence of renal cancer in the combination of
ADPKD and ESRD was two to three times more than in ESRD
patients alone (Hajj et al.,2009).
Nouth reported a wide spectrum of tumor histology distinct
from sporadic RCC in 34 ESRD patients that underwent RN for
renal cancer. Pathologic sub types included acquired cystic dis-
ease (ACD) associated RCC, mucinous tubular, spindle cell, and
Xp11.2 translocation renal cell carcinoma. In 9/15 patients with
a duration of dialysis less than 10years, conventional clear cell
was the predominant histology whereas ACD associated RCC was
predominant (7/12) in those with dialysis of greater than 10years
(Nouth et al., 2009). Suson reported 15 post transplant patients
who underwent nephrectomy for renal masses in their native kid-
ney. A total of 22 renal units were removed and a total of 18
cancers, 10 of which were P1, were resected. There were 11 papil-
lary, 4 clear cell, and 3 chromophobe cancers. Only one patient in
this experience developed metastatic disease (Suson et al., 2011).
These reports, when taken together, describe a propensity for the
development of a wide range of renal cortical cancers in patients
withESRDwhoserenaltumorsasawholemayhavelessmetastatic
potential than sporadic renal cancers.
CHRONIC KIDNEY DISEASE: PREVALENT, SERIOUS, AND
UNDERAPPRECIATED DISEASE
Chronic kidney disease,deﬁned as an estimated glomerular ﬁltra-
tion rate (eGFR) of less than 60ml/min/1.73m2, is increasingly
viewed as a major public health problem in the United States and
since 2003 is considered an independent cardiovascular risk fac-
tor (Kidney Disease Outcome Quality Initiative,2002; Chobanian
et al., 2003; Sarnak et al., 2003; Ritz and McClellan, 2004; Shlipak
et al., 2005). The prevalence of CKD in the general population is
4% but may be as high as 30% in the elderly population. An esti-
mated 19 million adults in the United States have CKD and by the
year 2030,2 million of these will progress to ESRD and be in need
of chronic dialysis or renal transplantation (Coresh et al., 2007).
Worldwide epidemics of cardiovascular disease, obesity, hyper-
tension, and diabetes, all of which can have adverse effects on
the kidney, have gained increasing attention but their contribu-
tion to the development of CKD has gone relatively unnoticed
amongst clinicians and patients alike. The adverse impact of CKD
oncardiovasculardiseaseissigniﬁcantasCKDprogressestoESRD
(Stenvinkel, 2010). A study by Go involving 1,120,295 patients
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demonstrated a direct correlation between the stages of CKD and
rates of hospitalization, cardiovascular events, and death, which
occurred before overt ESRD requiring dialysis or renal trans-
plantation (Go et al., 2004). As kidney function deteriorated, the
percentage of patients with two associated cardiovascular risk fac-
torsincreasedfrom34.7%(Stage1and2CKD)to83.6%(forstage
3) to 100% for stage 4 and 5 subjects. Patients with CKD are more
likely to require medical interventions to treat cardiovascular dis-
easethanthosewithnormalrenalfunction.Thelowprevalenceof
patients with Stage 4 or 5 CKD is attributable to a 5-year survival
rate of only 30% (Foley et al., 2005).
The adverse impact of CKD increases as the patient popula-
tion at risk ages. Stevens explored the prevalence and impact of
CKD in patients over 65 in the USA in a large combined data
setwhichincludedNHANES,KEEP,anda5%sampleof Medicare
(n =1,236,946)andfoundthatastheeGFRdecreased,thecomor-
bid metabolic conditions of anemia, hypocalcemia, hyperphos-
phatemia, and hyperparathyroidism increased. The subsequent
impactof theseconditionsonoverallhealthhasmadeCKDacrit-
ical disease in need of increased awareness by the entire medical
community (Stevens et al.,2010). This high prevalence of CKD in
the aging and elderly effects is superimposed upon the very same
patient population most at risk for the development of cancer.
CKD: ASSOCIATIONS WITH CANCER AND KIDNEY CANCER
As with ESRD,there are now reports indicating that patients with
CKD are at higher risk for the development of cancer in addition
to cardiovascular disease. Weng evaluated 123,717 adults in Tai-
wan in 1998 and calculated their eGFR. After a median of over
7years, mortality was ascertained by computer linkage to their
national death registry. The investigators found a higher overall
cancer mortality in CKD patients vs. non-CKD patients. CKD
was associated with an adjusted hazard ratio of 1.74, 3.3, and 7.3
for liver, kidney, and urothelial cancers respectively (Weng et al.,
2011). Wong evaluated 3654 patients in Australia aged 49–97 and
followed them for a mean 10.1years. Cancer developed in 711
patients (19.5%). Men with CKD 3 were at increased risk for the
development of cancer starting at an eGFR of 55 (HR 1.39). For
every 10ml/min decrement decline in eGFR, the risk of cancer
rose 29% and was at greatest risk for an eGFR of 40 (HR 3.01)
with lung and urinary tract the most likely diagnoses (Wong et al.,
2009).
Cancer patients appear to have a higher rate of CKD than the
general population. Launay-Vacker et al. (2007) evaluated 4684
patients with cancer, median age 58, and reported that 12 and
20% had an eGFR less than 60ml/min/1.73m2 by the modiﬁ-
cation in diet and renal disease (MDRD) and Cockcroft Gault
equations respectively. Canter reported the prevalence of base-
line CKD in 1114 patients presenting with solid renal tumors.
Twenty-two percent had stage 3 CKD or greater despite 88%
having a serum creatinine within normal limits (<1.4mg/dl).
In a sub group of 282 patients 70years or older, 113 (40%)
had CKD stage 3 (Huang et al., 2006). These results are similar
to those ﬁrst reported by MSKCC investigators which demon-
strated a 26% rate of CKD in 662 patients with small renal
tumorsandaserumcreatininewithinnormallimits(Huangetal.,
2006).
CANCER AND KIDNEY CANCER ASSOCIATED
NEPHROPATHOLOGY
The extent to which ESRD, CKD associated nephropathological
changes are simply associated with kidney tumors or cause kid-
ney tumors is not known and is of great current interest amongst
urological oncologists, nephrologists, and pathologists alike. In
patientswithESRD,numerousrenalcystsdevelopandpersistently
grow in native kidneys even after transplantation. Goh reported
10 asymptomatic transplant recipients who developed renal cell
carcinoma in native kidneys at a median of 5.8years while their
grafts were functioning at greater than 90% rate. The patients
at greatest risk for developing renal cancer were those with pre-
existing renal cysts and those on dialysis the longest (Goh and
Vathsala, 2011). In patients without ESRD/CKD and renal can-
cer, many nephropathological changes are observed. Bijol from
Harvard Medical School examined the non-tumor bearing nor-
mal appearing kidney in 110 nephrectomy specimens resected for
kidney cancer. Extensive and unsuspected underlying renal dis-
easeincludingvascularsclerosis,diabeticnephropathy,glomerular
hypertrophy, mesangial expansion, and diffuse glomerulosclero-
sis was reported. Only 10% of patients had completely normal
renal tissue adjacent to the tumor (Bijol et al., 2006). Henriksen
et al. (2009) conﬁrmed a wide range of kidney abnormalities in
thenon-neoplastickidney,includingmesangialsclerosisorhyper-
cellularity, segmental sclerosis, crescent formation, glomerulitis,
andglomerularbasementmembranedisease.Pathologistsarenow
being urged to routinely report these ﬁndings in routine tumor
nephrectomy specimens (Bonsib and Pei, 2010).
The precise mechanisms by which the uremic state, dialysis,
and transplantation causes malignant transformation in the kid-
ney are unknown and are likely multi-factorial. Cancer induced
paraneoplastic nephropathy, exposure to toxins, viral mediated
carcinogenesis, immune inhibition, and circulating toxins have
all been implicated in the process of increased cancer in patients
with ESRD/CKD (Stengel, 2010). Retention of uremic toxins,
such as p-cresol, could promote malignant transformation by
theirinhibitoryeffectontheimmunesystemandtransendothelial
leukocyte migration (Dou et al., 2002; Faure et al., 2006). Future
research is required to deﬁne the precise mechanism by which
uremic conditions predispose patients to cancer.
RENAL TUMOR SURGERY AND NEW CONCERNS FOR CKD
After World War 2, improvements in surgical technique and peri-
operative care allowed for the radical resection of massive renal
tumors (RN) with results indicating excellent local tumor con-
trol and long term survival in greater than 50% of patients in
the absence of metastatic or regional nodal disease (Russo, 2006,
2011). However, a historic misconception was propagated that
implied that the loss of a kidney to cancer surgery and the subse-
quent and expected rise in serum creatinine would have minimal
if any impact of the patient’s health as long as there was a normal
contra lateral kidney. The renal transplant literature was cited as
the clinical evidence to support this view since patients undergo-
ing donor nephrectomy were reported not to have higher rates
of kidney failure requiring dialysis or death (Segev et al., 2010).
However, distinct differences between kidney donors and kidney
tumor patients exist. Donors were carefully screened for medical
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co-morbidities and are generally young (age 45 or less; Fehrman-
Ekholmetal.,2001;Goldfarbetal.,2001).Incontrast,renaltumor
patientsarenotscreened,areolder(meanage61years),andmany
have signiﬁcant co-morbidities affecting baseline kidney func-
tionincludingmetabolicsyndrome,hypertension,coronaryartery
disease, obesity, vascular disease, and diabetes. In addition, as
patient’s age, particularly beyond 60years, nephrons atrophy and
glomerular ﬁltration rate progressively decreases (Kaplan et al.,
1975).
Evidence that RN could cause a signiﬁcant rise in the serum
creatinine when compared to PN in patients with renal corti-
cal tumors of 4cm or less was published by investigators from
Mayo Clinic and MSKCC in 2000 and 2002, respectively. RN
patients were more likely to have elevated serum creatinine lev-
els to >2.0ng/ml and proteinuria (Mayo Study; Lau et al., 2000),
a persistent ﬁnding even when study patients were carefully
matched for associated risk factors (MSKCC study) including dia-
betes, smoking history, pre-operative serum creatinine, and ASA
score (McKiernan et al., 2002). In both studies, oncological out-
comes were highly favorable (>90% survival rates) whether PN
or RN was performed. A new and emerging concern that the
overzealous use of RN, particularly in elderly patients with small
renal masses and common co-morbidities that can affect renal
function, could be cause or worsen pre-existing CKD became a
focus of intensive research. MSKCC investigators used a widely
available formula, the MDRD equation (Stevens et al., 2006;
http://www.nephron.com/MDRD_GFR.cgi), to eGFR in a retro-
spective cohort study of 662 patients with a normal serum creati-
nineand2healthykidneysthatunderwenteitherelectivePNorRN
for a RCT 4cm or less in diameter. To their surprise, 171 patients
(26%)hadpre-existingCKD(GFR<60).Datawasanalyzedusing
two threshold deﬁnitions of CKD, a GFR <60ml/min/1.73m2 or
a GFR <45ml/min/1.73m2. After surgery, the 3-year probability
of freedom from new onset of GFR <60 was 80% after PN but
only 35% after RN. Corresponding values for 3year probability
of freedom from a GFR <45, a more severe level of CKD, was
95% for PN and 64% for RN. Multivariable analysis indicated
that RN was an independent risk factor for the development of
new onset CKD (Huang et al., 2006). Mayo Clinic investigators
identiﬁed 648 patients from 1989 to 2003 treated with RN or PN
for a solitary renal tumor less than or equal to 4cm with a nor-
mal contra lateral kidney. In 327 patients younger than 65 it was
found that RN was signiﬁcantly associated with an increased risk
of death which persisted after adjusting for year of surgery, dia-
betes,Charlson–Romano index,and tumor histology (Thompson
et al.,2008).
Using the Surveillance, Epidemiology, and End Results cancer
registry data linked with Medicare claims, MSKCC investigators
studied2991patientsolderthan65yearsforresectedrenaltumors
of 4cm or less from 1995 to 2002. A total of 254 patients (81%)
underwent RN and 556 patients underwent PN. During a median
follow up of 4years, 609 patients experienced a cardiovascular
event and 892 patients died. After adjusting for pre-operative
demographic and co-morbidity variables,RN was associated with
a 1.38 times increased risk of overall mortality and a 1.4 times
greaternumberof cardiovascularevents(Huangetal.,2009).Sim-
ilar results were reported in patients undergoing laparoscopic RN
and PN (Foyil et al.,2008). Because of these reports,urologists are
now increasingly aware that CKD can be caused or pre-existing
CKD signiﬁcantly worsened by the liberal use of RN for the treat-
ment of the small renal mass (Lane et al., 2009). Short term end
points, including length of hospital stay, analgesic requirements,
and cosmetic elements viewed by many as the reason to elect
laparoscopic RN, must now be tempered by the guaranteed renal
functional decline after RN. The most recent AUA guidelines for
the management of the small renal tumor emphasize these points
and strongly support the use of PN whenever technically feasible
(Campbell et al.,2009).
RADICAL NEPHRECTOMY IS OVER-UTILIZED
Despite the above well described oncological and medical argu-
ments in the contemporary literature supporting PN as the ideal
treatment for small renal masses, the urological oncology com-
munity continues to use RN as the predominant treatment of
the small renal mass. A cross sectional view of clinical practice
using the Nationwide Inpatient Sample, revealed that only 7.5%
of kidney tumor operations in the United States 1988–2002 were
PN (Hollenback et al.,2006). Using the surveillance epidemiology
andendresults(SEER)database,investigatorsfromtheUniversity
of Michigan reported that only 20% of all renal cortical tumors
between2and4cmweretreatedbyPN(Milleretal.,2006a).Using
the SEER data base linked to Medicare claims, MSKCC investiga-
tors reported a PN utilization rate of only 19% for T1a tumors
(4cm or less; Huang et al., 2009). Interestingly and for uncer-
tain reasons, women and elderly patients are more likely to be
treated with RN (Dulabon et al., 2010). Many urologists believe
a “quick” RN in an elderly patient would expose the patient to
fewer post operative complications than would a PN. However,
MSKCC investigators evaluated age and type of procedure per-
formed in 1712 patients with kidney tumors found a lack of
statistical evidence that the risk of complications associated with
PN increased with advancing age. Furthermore, no evidence was
reported linking age to estimated blood loss or operative time.
Giventheadvantagesof renalfunctionalpreservation,theauthors
concluded that elderly patients should be perfectly eligible for PN
(Lowrance et al., 2010). As mentioned above, the elderly patients
have the highest rates of underlying CKD and are most vulnerable
to the adverse impact of RN.
Although the urology literature has a great many articles writ-
ten concerning the use of laparoscopic techniques to resect kid-
ney tumors, the penetrance of laparoscopic RN according to the
National Inpatient Sample from 1991 to 2003 was only 4.6% with
a peak incidence of 16% in 2003. This data indicates that the bulk
of“kidney wasting operations”are being done by traditional open
surgical approaches (Miller et al., 2006b). In England, a similar
under-utilization of PN was reported in 2002 with only 108 (4%)
PN out of 2671 nephrectomies performed (Nuttail et al., 2005).
InvestigatorsatMSKCCtrackednephrectomyusein1533patients
between 2000 and 2007 excluding patients with bilateral tumors
and tumors in a solitary kidney and including only patients with
an eGFR of greater than 45ml/min/1.73m2. Overall 854 (56%)
patients underwent PN and 679 (44%) underwent RN. In the 820
patients with a renal tumor of 4cm or less, the frequency of PN
increased from 69% in 2000 to 89% in 2007. In the 365 patients
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with a renal tumor from 4 to 7cm, the frequency of PN increased
from 20% in 2000 to 60% in 2007. Despite a commitment to
kidney sparing operations during this time frame by the MSKCC
group, multivariate analysis indicated that PN was a signiﬁcantly
favoredapproachformales,youngerpatients,smallertumors,and
open surgeons (Thompson et al., 2009).
CONCLUSION
A previously understood association between ESRD patient’s
native kidneys and the development of kidney cancer has been
extended now to include patients with CKD. CKD is an increasing
public health problem in the United States and now considered
an independent risk factor for the development of cardiovascular
morbidity and mortality. CKD is multi-factorial and may be due
to common medical conditions including hypertension, diabetes,
obesity and vascular disease. As the eGFR decreases, metabolic
complications increase with patients over the age of 65years par-
ticularly susceptible. These aging patients also have the greatest
vulnerability to the development of cancer. Patients with cancer
in general and kidney cancer in particular may have concomitant
CKD rates as high as 40%. In the non-neoplastic kidney at the
time of nephrectomy, extensive nephropathological ﬁndings are
observed in the vast majority of patients. It is not clear if these
changes are a direct cause of renal neoplasia or a result of medical
co-morbidities that are prevalent in the kidney tumor patients.
The precise mechanism by which the uremic state causes malig-
nant transformation is not known but it is speculated that uremic
toxins, viral mediators, and immune inhibition could play a role
intheincreasedrateof kidneycancerseeninESRD/CKDpatients.
For surgeons operating on small renal tumors, it is now clear that
PN provides equivalent oncological results to RN while at the
same time maximally preserving renal function and preventing or
delaying the onset of CKD and its late cardiovascular morbidity
and mortality. Despite a decade of clinical evidence in support of
kidney preservation surgical techniques, RN remains overused in
the United States and abroad. Formal support for PN in the man-
agement of small renal masses has been made by major urological
surgical organizations. A working knowledge of the bi directional
relationship of CKD/ESRD and the surgical management of renal
tumors is now essential for all urological oncologists.
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